Biotherapy Services Limited
Biotherapy Services Limited are a multidisciplinary team of clinicians, scientists, pharmacists, and healthcare professionals focused on the delivery of safe and effective autologous biotherapies for a range of clinical applications.
Our particular focus is on wound healing and tissue regeneration, using blood-derived products which are rich in white blood cells and platelets that harness the healing properties of the body. We rely on state-of-the-art technology and patented proprietary processes, working to GMP pharmaceutical manufacturing standards, to help patients in need.
Autologous biological therapies, such as the proprietary RAPID™ Biodynamic Haematogel, concentrate the cells that allow the body to heal itself and kick-start the patient’s own healing processes.
The RAPID™ Biodynamic Haematogel is made up of concentrated platelets derived from the patient’s own blood, which are activated by autologous thrombin to release healing growth factors, cell signalling molecules, and proteins that work at a cellular level.
Our RAPID™ Biodynamic Haematogel wound care treatment has been defined by the MHRA as the first-in-world, first-in-class point of care wound care treatment, classified as a medicine.
On the 8th November 2018, the Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee gave approval to commence the RAPID-1DFU Clinical Trial.
RAPID-1 Diabetic Foot Ulcer Trial ISRCTN55474813
The purpose of this Trial is to investigate the safety and efficacy of the RAPID™ Gel when treating Diabetic Foot Ulcers (DFUs). Recruited patients will be randomly sent to 1 of 2 trial arms:
The trial commenced on the 8th March 2019 at the Royal London Hospital, and is still underway.
The trial is currently taking place at three different sites:
For more information about the Trial, play the video to hear Mr Sandip Sarkar giving his insight into the RAPID-1DFU Trial!